Priority Tech Holdings: Q1 Earnings Insights

Priority Tech Holdings (NASDAQ:PRTH) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:30 AM. Here’s…

Priority Tech Holdings (NASDAQ:PRTH) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Priority Tech Holdings missed estimated earnings by 7.14%, reporting an EPS of $-0.15 versus an estimate of $-0.14.

Revenue was up $31.79 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.08 which was followed by a 3.85% increase in the share price the next day.

Here’s a look at Priority Tech Holdings’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.07 -0.06 0.02 -0.01
EPS Actual -0.15 -0.13 -0.11 -0.11
Revenue Estimate 165.25M 170.34M 162.23M 151.76M
Revenue Actual 177.56M 166.42M 166.43M 153.24M

To track all earnings releases for Priority Tech Holdings visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB